US 12,331,005 B2
Ionizable cationic lipids
Frank DeRosa, Waltham, MA (US); Braydon Charles Guild, Waltham, MA (US); and Michael Heartlein, Waltham, MA (US)
Assigned to TRANSLATE BIO, INC., Waltham, MA (US)
Filed by Translate Bio, Inc., Waltham, MA (US)
Filed on Aug. 7, 2024, as Appl. No. 18/797,392.
Application 18/797,392 is a continuation of application No. 18/646,567, filed on Apr. 25, 2024.
Application 18/646,567 is a continuation of application No. 16/983,121, filed on Aug. 3, 2020, granted, now 11,999,675, issued on Jun. 4, 2024.
Application 16/983,121 is a continuation of application No. 16/100,853, filed on Aug. 10, 2018, granted, now 10,766,852, issued on Sep. 8, 2020.
Application 16/100,853 is a continuation of application No. 15/368,280, filed on Dec. 2, 2016, granted, now 10,065,919, issued on Sep. 4, 2018.
Application 15/368,280 is a continuation of application No. 14/389,023, granted, now 9,546,128, issued on Jan. 17, 2017, previously published as PCT/US2013/034602, filed on Mar. 29, 2013.
Claims priority of provisional application 61/617,468, filed on Mar. 29, 2012.
Prior Publication US 2024/0383841 A1, Nov. 21, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/1271 (2025.01); A61K 9/1272 (2025.01); A61K 9/50 (2006.01); A61K 38/18 (2006.01); A61K 38/47 (2006.01); A61K 47/00 (2006.01); A61K 48/00 (2006.01); C07C 211/21 (2006.01); C12N 15/85 (2006.01)
CPC C07C 211/21 (2013.01) [A61K 9/1271 (2013.01); A61K 9/1272 (2013.01); A61K 9/5015 (2013.01); A61K 38/1816 (2013.01); A61K 38/47 (2013.01); C12N 15/85 (2013.01); C12Y 302/01023 (2013.01)] 17 Claims
 
1. A lipid nanoparticle comprising:
mRNA;
one or more helper lipids, one or more non-cationic lipids, and/or one or more PEG-modified lipids; and
a cationic lipid having the structure:

OG Complex Work Unit Chemistry
wherein
R1 and R2 are each independently an optionally substituted saturated C1-C20 alkyl or an optionally substituted variably unsaturated C2-C20 alkenyl
L1 is selected from the group consisting of hydrogen, an optionally substituted C3-C30 alkyl, and an optionally substituted variably unsaturated C3-C30 alkenyl;
L2 is selected from the group consisting of an optionally substituted C3-C30 alkyl and an optionally substituted variably unsaturated C3-C30 alkenyl;
m is three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty;
o is zero, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty; and
n is zero, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty.